Physician profile
Deep Garg
NPI 1609155233
$1,185.31
in general payments reported to CMS, 2019-2025
19 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2024: $35.26 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $341.27 | 2025 | Monoferric |
| Incyte Corporation | $160.41 | 2021-2025 | Jakafi |
| Eisai INC. | $124.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.68 | 2025 | Reblozyl |
| Boston Scientific Corporation | $75.88 | 2025 | Watchman Flx |
| Novo Nordisk INC | $68.67 | 2025 | Wegovy |
| Geron Corporation | $48.12 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.89 | 2025 | Iclusig, Ninlaro |
| Genentech USA, INC. | $36.32 | 2024-2025 | Tecentriq |
| Tempus Ai, INC | $26.16 | 2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.38 | 2025 | Qinlock, Romvimza |
| Sobi, INC | $17.76 | 2025 | |
| Glaxosmithkline, LLC. | $17.46 | 2025 | Jemperli, Zejula |
| Janssen Biotech, INC. | $16.41 | 2025 | Erleada |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.85 | 2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $15.23 | 2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $14.73 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $13.73 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.